References
- American Geriatrics Society 2015 Beers Criteria Update Expert Panel: American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2015; 63: 2227-2246.
- Arranz FJ, Ros S. Effects of comorbidity and polypharmacy on the clinical usefulness of sertraline in elderly depressed patients: an open multicentre study. J Affect Disord. 1997; 46: 285-91.
- Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009; 373: 746-58.
- Dew MA, Whyte EM, Lenze EJ, Houck PR, Mulsant BH, Pollock BG, Stack JA, Bensasi S, Reynolds CF. Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. Am J Psychiatry. 2007; 164: 892–899
- Doan J, Zakrzewski-Jakubiak H, Roy J, Turgeon J, Tannenbaum C. Prevalence and risk of potential cytochrome P450-mediated drug-drug interactions in older hospitalized patients with polypharmacy. Ann Pharmacother. 2013; 47: 324-332
- Driscoll HC, Basinski J, Mulsant BH, Butters MA, Dew MA, Houck PR, Mazumdar S, Miller MD, Pollock BG, Stack JA, Schlernitzauer MA, Reynolds CF. Late-onset major depression: clinical and treatment-response variability. Int J Geriatr Psychiatry. 2005; 20: 661–667
- Driscoll HC, Karp JF, Dew MA, Reynolds CF. Getting better, getting well: understanding and managing partial and non-response to pharmacological treatment of non-psychotic major depression in old age. Drugs Aging. 2007; 24: 801–814
- Gerson S, Belin TR, Kaufman A, Mintz J, Jarvik L. Pharmacological and psychological treatments for depressed older patients: a metaanalysis and overview of recent findings. Harv Rev Psychiatry. 1999; 7: 1-28.
- Higgins JPT, Altman DG, Stearne JAC (editors). Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration (2011) www.cochrane-handbook.org.Accessed, March 2017.
- Holt S, Schmiedl S, Thürmann PA. Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int. 2010; 107: 543-51.
- Jasiak NM, Bostwick JR. Risk of QT/QTc prolongation among newer non-SSRI antidepressants. Ann Pharmacother. 2014; 48: 1620-8.
- Khan A, Shad MU, Preskorn SH. Lack of sertraline efficacy probably due to an interaction with carbamazepine. J Clin Psychiatry. 2000; 61: 526-7.
- Mangerud WL, Bjerkeset O, Holmen TL, Lydersen S, Indredavik MS. Smoking, alcohol consumption, and drug use among adolescents with psychiatric disorders compared with a population based sample. J Adolesc. 2014; 37: 1189-1199.
- Mann E, Haastert B, Böhmdorfer B, Frühwald T, Iglseder B, Roller-Wirnsberger R, Meyer G. Prevalence and associations of potentially inappropriate prescriptions in Austrian nursing home residents: secondary analysis of a cross-sectional study. Wien Klin Wochenschr. 2013; 125: 180-188.
- McCusker J, Cole M, Keller E, Bellavance F, Berard A. Effectiveness of treatments of depression in older ambulatory patients. Arch Intern Med. 1998; 13; 158: 705-12.
- Mittmann N, Herrmann N, Einarson TR, Busto UE, Lanctôt KL, Liu BA, Shulman KI, Silver IL, Narango CA, Shear NH. The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord. 1997; 46: 191-217.
- Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005; 33: 262-70.
- O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015; 44: 213-8.
- Practice guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, APA. American Psychiatric Association (APA) treatment guidelines (2010). Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
- Quality and Outwork framework 2012 (Accessed on 27 of January 2018): http://www.nhsemployers.org/Aboutus/Publications/Documents/QOF_2012-13.pdf
- Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 349: g7647.
- Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR∗D) trial: a review. Can J Psychiatry. 2010; 55: 126-35.
- Štuhec M. Duloxetine-induced life-threatening long QT syndrome. Wien Klin Wochenschr. 2013; 125: 165-6
- Tampi RR, Balderas M, Carter KV, Tampi DJ, Moca M, Knudsen A, May J. Citalopram, QTc Prolongation, and Torsades de Pointes. Psychosomatics. 2015; 56: 36-43.
- Thorlund K, Druyts E, Wu P, Balijepalli C, Keohane D, Mills E. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc. 2015; 63: 1002-9.
- Wilkinson P, Izmeth Z. Continuation and maintenance treatments for depression in older people. Cochrane Database Syst Rev. 2016; 9: CD006727.